Valuation: InMode Ltd.

Market Cap 871M 14.81B 752M 707M 643M 1.21B 83.27B 1.23B 8.28B 3.24B 41.7B 3.27B 3.2B 139B P/E 2026 *
13.5x
P/E 2027 * 12.6x
Enterprise Value 871M 14.81B 752M 707M 643M 1.21B 83.27B 1.23B 8.28B 3.24B 41.7B 3.27B 3.2B 139B EV / Sales 2026 *
2.35x
EV / Sales 2027 * 2.3x
Free-Float
60.56%
Yield 2026 *
-
Yield 2027 * -
Current year 240.26
Extreme 240.26
240.26
1 year 240.26
Extreme 240.26
240.26
3 years 240.26
Extreme 240.26
240.26
5 years 240.26
Extreme 240.26
240.26
10 years 240.26
Extreme 240.26
240.26
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2008-01-01
Chief Executive Officer 73 2008-01-01
Director of Finance/CFO 41 2026-05-18
Director TitleAgeSince
Chairman 73 2008-01-01
Director/Board Member 59 2019-08-06
Chairman 67 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 871M
+0.16%-1.67%+20.95%+10.02% 218B
-0.40%-3.66%-3.49%-20.22% 142B
-0.54%-0.74%-18.87%+34.61% 139B
-0.61%+1.59%-50.26%+0.63% 75.11B
-0.47%-1.42%+15.86%+18.08% 52.8B
-1.11%-0.71%-17.66%-15.62% 50.66B
-0.43%-0.75%+24.93%+22.13% 41.95B
-0.63%-0.56%+41.49%+49.90% 40.49B
-1.47%-0.41%-0.72%+6.21% 33.28B
Average -0.52%+1.61%+1.36%+11.75% 88.17B
Weighted average by Cap. -0.35%+1.12%+0.38%+9.44%

Financials

2026 *2027 *
Net sales 370M 6.3B 320M 301M 273M 514M 35.41B 522M 3.52B 1.38B 17.73B 1.39B 1.36B 58.92B 379M 6.44B 327M 307M 280M 526M 36.22B 534M 3.6B 1.41B 18.14B 1.42B 1.39B 60.27B
Net income 68.51M 1.17B 59.17M 55.6M 50.57M 95.07M 6.55B 96.64M 651M 255M 3.28B 257M 252M 10.9B 71.43M 1.22B 61.69M 57.97M 52.72M 99.12M 6.83B 101M 679M 266M 3.42B 268M 262M 11.37B
Net Debt - -
Logo InMode Ltd.
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Employees
660
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
15.15USD
Average target price
16.17USD
Spread / Average Target
+6.71%

Quarterly revenue - Rate of surprise